Related Experiment Videos
Bactericidal activity of vancomycin in cerebrospinal fluid
1Institute for Hygiene, Leopold-Franzens-University of Innsbruck, University Hospital of Innsbruck, Austria. waldemar.gottardi@uibk.ac.at
Antimicrobial Agents and Chemotherapy
|August 3, 1999
Summary
Intraventricular vancomycin effectively treats shunt-associated staphylococcal ventriculitis. High concentrations and 24-48 hour incubation achieve bacterial reduction, supporting specific dosing regimens.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Shunt-associated ventriculitis is a serious complication requiring effective treatment.
- Intraventricular vancomycin is a potential therapeutic option for this condition.
Observation:
- In vitro studies evaluated vancomycin activity against Staphylococcus aureus and Staphylococcus epidermidis in cerebrospinal fluid.
- Time-kill curves demonstrated comparable efficacy for vancomycin concentrations of 10, 100, and 300 microg/ml.
- Bacterial reduction required 24 to 48 hours of incubation, with 5 microg/ml showing slightly lower, though not significant, activity.
Findings:
- In vitro vancomycin concentrations of 5-300 microg/ml demonstrated significant bacterial kill against S. aureus and S. epidermidis.
- In vivo findings in an infant mirrored in vitro results, supporting the efficacy of local vancomycin administration.
- Optimal treatment regimens should aim for trough vancomycin levels between 5 and 10 microg/ml.
Implications:
- These findings support specific time-dose regimens for intraventricular vancomycin in treating shunt-associated ventriculitis.
- Establishing optimal vancomycin trough levels can improve treatment outcomes and reduce bacterial resistance.
- Further research into tailored dosing strategies for intraventricular antibiotics is warranted.